person · Reporting owner
DUNCAN BARBARA GAYLE
Disclosed activity across 10 companies
Sign in to followReported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Adaptimmune Therapeutics PLCADAP · Entity 9824 | Director | July 01, 2022 | July 01, 2022 |
| Atea Pharmaceuticals, Inc.AVIR · Entity 5580 | Director | June 18, 2026 | June 23, 2026 |
| HALOZYME THERAPEUTICS, INC.HALO · Entity 793 | Director | May 05, 2026 | May 07, 2026 |
| INTERCEPT PHARMACEUTICALS, INC.ICPT · Entity 108343 | Chief Accounting Officer | October 03, 2016 | October 06, 2016 |
| Innoviva, Inc.INVA · Entity 4679 | Director | April 20, 2017 | April 24, 2017 |
| Ovid Therapeutics Inc.OVID · Entity 5411 | Director | February 26, 2026 | March 02, 2026 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Adaptimmune Therapeutics PLC
Report date July 01, 2022 · Filed July 01, 2022
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Option to purchase Ordinary SharesSEC Table II · derivative / convertible security · Conversion / exercise price $0.28 · Expires 2032-07-01 | Direct | 500,000 |
Reported balance
After 2022-07-01 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2022-07-01 · Grant · Acquired 500,000 · Balance 500,000 F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount.
Atea Pharmaceuticals, Inc.
Report date June 18, 2026 · Filed June 23, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 92,350 |
Reported balance
After 2026-06-18 transaction · row 1
1 source rowRow 1 · 2026-06-18 · Exercise / conversion · Acquired 29,600 · Balance 92,350 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2026-06-18 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-06-18 · Exercise / conversion · Disposed 29,600 · Balance 0 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2: The RSUs vested in full on June 18, 2026. |
| Restricted Stock UnitsSEC Table II · derivative / convertible security | Direct | 26,700 |
Reported balance
After 2026-06-18 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2026-06-18 · Grant · Acquired 26,700 · Balance 26,700 F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.36 · Expires 2036-06-17 | Direct | 37,700 |
Reported balance
After 2026-06-18 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2026-06-18 · Grant · Acquired 37,700 · Balance 37,700 F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock.
F2: The RSUs vested in full on June 18, 2026.
F3: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date.
F4: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date.
HALOZYME THERAPEUTICS, INC.
Report date May 05, 2026 · Filed May 07, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 23,715 |
Reported balance
After 2026-05-05 transaction · row 1
1 source rowRow 1 · 2026-05-05 · Grant · Acquired 3,796 · Balance 23,715 F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. |
| Option to Purchase Common StockSEC Table II · derivative / convertible security · Conversion / exercise price $65.87 · Expires 2036-05-05 | Direct | 6,040 |
Reported balance
After 2026-05-05 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2026-05-05 · Grant · Acquired 6,040 · Balance 6,040 F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director.
F2: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders.
INTERCEPT PHARMACEUTICALS, INC.
Report date October 03, 2016 · Filed October 06, 2016
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 30,661 |
Reported balance
After 2016-10-03 transaction · row 1
1 source rowRow 1 · 2016-10-03 · Sale · Disposed 147 · Balance 30,661 F1: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee. |
Filing footnotes · ownership attribution and instrument terms
F1: Each employee of the Issuer who has received restricted stock awards has agreed to a mandatory sale of a sufficient number of shares of common stock to cover his or her withholding tax amounts upon the vesting of such restricted stock awards. The sales denoted here were made pursuant to such agreement to cover withholding tax obligations of the employee.
Innoviva, Inc.
Report date April 20, 2017 · Filed April 24, 2017
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 52,318 |
Reported balance
After 2017-04-20 transaction · row 1
1 source rowRow 1 · 2017-04-20 · Grant · Acquired 19,857 · Balance 52,318 F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The Reporting Person was granted restricted stock units ("RSUs"). 100% of the RSUs will vest at the sooner of the next annual shareholder meeting or the one-year anniversary of grant, subject to the Reporting Person's continuous service as an Outside Director through the applicable vesting date.
Ovid Therapeutics Inc.
Report date February 26, 2026 · Filed March 02, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Employee Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.65 · Expires 2036-02-25 | Direct | 65,000 |
Reported balance
After 2026-02-26 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2026-02-26 · Grant · Acquired 65,000 · Balance 65,000 F1: The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date. |
Filing footnotes · ownership attribution and instrument terms
F1: The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date.
Past disclosures · reporting ended (4)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Aevi Genomic Medicine, LLC
Report date February 03, 2020 · Filed February 05, 2020
Section 16 reporting ended · disclosed 2020-02-05. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 1
1 source rowRow 1 · 2020-02-03 · Disposition to issuer · Disposed 59,524 · Balance 0 F1: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.55 · Expires 2028-04-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-02-03 · Disposition to issuer · Disposed 50,000 · Balance 0 F2: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $1.32 · Expires 2027-06-22 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-02-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F3: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $4.83 · Expires 2026-04-15 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2020-02-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F4: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Stock Option (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $8.09 · Expires 2025-07-22 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2020-02-03 · Disposition to issuer · Disposed 40,000 · Balance 0 F5: This option, which became exercisable on July 22, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger. |
| Warrant (Right to Purchase)SEC Table II · derivative / convertible security · Conversion / exercise price $2.84 · Expires 2022-10-17 | Direct | 0 |
Reported balance
After 2020-02-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2020-02-03 · Disposition to issuer · Disposed 10,591 · Balance 0 F6: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void. |
Filing footnotes · ownership attribution and instrument terms
F1: Disposed of as a result of the merger pursuant to the previously announced Agreement and Plan of Merger and Reorganization by and among Cerecor Inc. ("Cerecor"), Genie Merger Sub, Inc., Second Genie Merger Sub, LLC and issuer (the "Merger"). At the effective time of the Merger, holders of issuer common stock received (A) the fraction of a share of Cerecor common stock equal to the exchange ratio of 0.0334 (B) one contingent value right, which represents the right to receive contingent payments upon the achievement of certain milestones and (C) cash in lieu of any fractional shares of Cerecor common stock.
F2: This option, which became exercisable on April 17, 2019, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F3: This option, which became exercisable on June 22, 2018, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F4: This option, which became exercisable on April 15, 2017, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F5: This option, which became exercisable on July 22, 2016, was automatically cancelled and ceased to exist without any consideration or payment pursuant to the Merger.
F6: This warrant, which was issued pursuant to a Securities Purchase Agreement dated August 9, 2017, was subsequently amended by the Amendment Agreement of Warrants to Purchase Common Stock dated December 5, 2019, whereby immediately prior to the Merger the warrants were automatically exercised in a cashless exercise. Given the exercise price of the outstanding warrants, the cashless exercise resulted in no shares of common stock being issued and the warrant was rendered null and void.
Fusion Pharmaceuticals Inc.
Report date June 04, 2024 · Filed June 04, 2024
Section 16 reporting ended · disclosed 2024-06-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $12.40 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-06-04 · Disposition to issuer · Disposed 30,000 · Balance 0 F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $8.15 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $3.60 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.64 | Direct | 0 |
Reported balance
After 2024-06-04 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2024-06-04 · Disposition to issuer · Disposed 17,000 · Balance 0 F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. |
Filing footnotes · ownership attribution and instrument terms
F1: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions.
F2: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions.
IMMUNOMEDICS INC
Report date October 23, 2020 · Filed October 23, 2020
Section 16 reporting ended · disclosed 2020-10-23. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 1
1 source rowRow 1 · 2020-10-23 · Disposition to issuer · Disposed 49,244 · Balance 0 F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2020-10-23 · Disposition to issuer · Disposed 6,540 · Balance 0 F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration. |
| Restricted Stock UnitSEC Table II · derivative / convertible security | Direct | 0 |
Reported balance
After 2020-10-23 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2020-10-23 · Disposition to issuer · Disposed 3,718 · Balance 0 F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time. |
Filing footnotes · ownership attribution and instrument terms
F1: In connection with the consummation of the Merger, at the Effective Time, each share of common stock, par value $0.01 per share, of the Company ("Common Stock") that was outstanding immediately prior to the Effective Time (other than certain shares specified in the Agreement) was automatically cancelled and converted into the right to receive $88.00 in cash (the "Offer Price"), without interest and subject to required withholding taxes.
F2: In connection with the consummation of the Merger, at the Effective Time, each option to purchase shares of Common Stock ("Stock Option") that was outstanding as of immediately prior to the Effective Time, whether vested or not vested, was automatically cancelled and converted into the right to receive an amount in cash equal to (i) the excess, if any, of the Offer Price over the exercise price payable per share subject to such Stock Option, multiplied by (ii) the total number of shares of Common Stock subject to such Stock Option immediately prior to the Effective Time. Any Stock Option that had an exercise price per share that was equal to or greater than the Offer Price was cancelled for no consideration.
F3: In connection with the consummation of the Merger, at the Effective Time, each restricted stock unit to acquire shares of Common Stock ("Restricted Stock Unit") that was outstanding as of immediately prior to the Effective Time, whether vested or unvested, was automatically cancelled and converted into the right to receive an amount in cash equal to (A) the Offer Price, multiplied by (B) the total number of shares of Common Stock subject to such Restricted Stock Unit immediately prior to the Effective Time.
Jounce Therapeutics, Inc.
Report date May 03, 2023 · Filed May 04, 2023
Section 16 reporting ended · disclosed 2023-05-04. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.21 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2023-05-03 · Disposition to issuer · Disposed 34,271 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $9.56 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 2
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 2 · 2023-05-03 · Disposition to issuer · Disposed 10,840 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.92 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 3
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 3 · 2023-05-03 · Disposition to issuer · Disposed 13,550 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $4.46 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 4
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 4 · 2023-05-03 · Disposition to issuer · Disposed 15,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.58 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 5
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 5 · 2023-05-03 · Disposition to issuer · Disposed 15,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $7.27 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 6
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 6 · 2023-05-03 · Disposition to issuer · Disposed 15,700 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $2.80 | Direct | 0 |
Reported balance
After 2023-05-03 transaction · row 7
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 7 · 2023-05-03 · Disposition to issuer · Disposed 20,000 · Balance 0 F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. |
Filing footnotes · ownership attribution and instrument terms
F1: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time").
F2: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 37,700 | $0.00 Strike: $4.36 | $0.00 |
DisclosureSEC source: 0001193125-26-279721 · ownership.xml · derivative · entry 4 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 37,700 Underlying: Common Stock · 37,700 shares Expires 2036-06-17 F4 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 18, 2026, such that the option shall be fully vested on June 18, 2027, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 26,700 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279721 · ownership.xml · derivative · entry 3 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,700 Underlying: Common Stock · 26,700 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F3 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F3 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after June 18, 2026 or (ii) June 18, 2027, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279721 · ownership.xml · derivative · entry 2 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vested in full on June 18, 2026. F2 · derivative.expiration_date: The RSUs vested in full on June 18, 2026. Read SEC document |
| June 18, 2026 Filed Jun 23, 2026 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0001193125-26-279721 · ownership.xml · nonDerivative · entry 1 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 92,350 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 6,040 | $0.00 Strike: $65.87 | $0.00 |
DisclosureSEC source: 0001159036-26-000060 · wk-form4_1778194928.xml · derivative · entry 2 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 6,040 Underlying: Common Stock · 6,040 shares Expires 2036-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2026 Filed May 7, 2026 23:02 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 3,796 | $0.00 | $0.00 |
DisclosureSEC source: 0001159036-26-000060 · wk-form4_1778194928.xml · nonDerivative · entry 1 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 23,715 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2027 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| February 26, 2026 Filed Mar 2, 2026 21:30 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantEmployee Stock Option (Right to Buy) · Derivative | 65,000 | $0.00 Strike: $1.65 | $0.00 |
DisclosureSEC source: 0001353128-26-000002 · form4-03022026_040309.xml · derivative · entry 1 DUNCAN BARBARA GAYLE · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 65,000 Underlying: Common Stock · 65,000 shares Expires 2036-02-25 F1 · derivative.exercise_date: The option will vest in full on February 26, 2027, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089609 · ownership.xml · derivative · entry 4 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 29,600 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F4 · derivative.exercise_date: The restricted stock units vested in full on June 20, 2025. F4 · derivative.expiration_date: The restricted stock units vested in full on June 20, 2025. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $3.25 | $0.00 |
DisclosureSEC source: 0000950170-25-089609 · ownership.xml · derivative · entry 3 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2035-06-19 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 20, 2025, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089609 · ownership.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 20, 2025 Filed Jun 24, 2025 22:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-25-089609 · ownership.xml · nonDerivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 62,750 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 5,750 | $0.00 Strike: $60.03 | $0.00 |
DisclosureSEC source: 0001415889-25-011769 · form4-05022025_080549.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 5,750 Underlying: Common Stock · 5,750 shares Expires 2035-05-01 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 01, 2025 Filed May 2, 2025 20:04 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 4,165 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-25-011769 · form4-05022025_080549.xml · nonDerivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 19,919 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 1, 2026 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| February 20, 2025 Filed Jun 18, 2025 20:45 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (right to buy) · Derivative | 45,000 | $0.00 Strike: $0.57 | $0.00 |
DisclosureSEC source: 0001415889-25-017696 · form4-06182025_040603.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 45,000 Underlying: Common Stock · 45,000 shares Expires 2035-02-19 F1 · derivative.exercise_date: The option will vest in full on February 20, 2026, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| December 12, 2024 Filed Dec 16, 2024 21:15 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 90,000 | $0.00 Strike: $1.06 | $0.00 |
DisclosureSEC source: 0001415889-24-029472 · form4-12162024_041213.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 90,000 Underlying: Common Stock · 90,000 shares Expires 2034-12-11 F1 · derivative.exercise_date: The shares will vest in 36 equal monthly installments, subject to the Reporting Person's continued services through such date. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 22:12 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 41,200 | $0.00 Strike: $3.44 | $0.00 |
DisclosureSEC source: 0000950170-24-076400 · ownership.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 41,200 Underlying: Common Stock · 41,200 shares Expires 2034-06-20 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 21, 2024, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 21, 2024 Filed Jun 21, 2024 22:12 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 29,600 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-076400 · ownership.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 29,600 Underlying: Common Stock · 29,600 shares Expires not disclosed F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The restricted stock units vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionRestricted Stock Units · Derivative | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074985 · ownership.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 33,150 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · derivative.exercise_price: Restricted stock units convert into common stock on a one-for-one basis. F2 · derivative.exercise_date: The restricted stock units are fully vested. F3 · derivative.expiration_date: The restricted stock units do not have an expiration date. Read SEC document |
| June 16, 2024 Filed Jun 18, 2024 21:00 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | Exercise / conversionCommon Stock | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000950170-24-074985 · ownership.xml · nonDerivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · price: Restricted stock units convert into common stock on a one-for-one basis. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:22 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $4.64 | Not disclosed |
DisclosureSEC source: 0000950170-24-068885 · ownership.xml · derivative · entry 4 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:22 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $3.60 | Not disclosed |
DisclosureSEC source: 0000950170-24-068885 · ownership.xml · derivative · entry 3 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:22 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 17,000 | Not disclosed Strike: $8.15 | Not disclosed |
DisclosureSEC source: 0000950170-24-068885 · ownership.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 17,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| June 04, 2024 Filed Jun 4, 2024 17:22 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | Disposition to issuerStock Option (Right to Buy) · Derivative | 30,000 | Not disclosed Strike: $12.40 | Not disclosed |
DisclosureSEC source: 0000950170-24-068885 · ownership.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 30,000 shares Expires not disclosed F1 · security: Pursuant to the Arrangement Agreement, dated as of March 18, 2024 (the "Arrangement Agreement"), by and among the Issuer, AstraZeneca AB, a public company with limited liability (Aktiebolag) incorporated under the laws of Sweden ("Parent") and 15863210 Canada Inc., a corporation formed under the Canada Business Corporations Act ("Purchaser"), Purchaser acquired all of the issued and outstanding common shares of the Issuer (collectively, the "Shares") effective as of 12:01 a.m. Toronto time on June 4, 2024 (the "Effective Time"). Following the Effective Time, each Share outstanding immediately prior to the Effective Time was assigned and transferred by the holder thereof to Purchaser in exchange for (i) US$21.00 in cash (the "Cash Consideration") plus (ii) one contingent value right (each, a "CVR") representing the contingent right to receive a cash payment equal to US$3.00, in each case subject to applicable tax withholdings and other source deductions. F2 · price: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.exercise_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. F2 · derivative.expiration_date: Pursuant to the terms of the Arrangement Agreement, immediately following the Effective Time, each option to purchase Shares granted (each, an "Option") with an exercise price that is less than the Cash Consideration and outstanding immediately prior to the Effective Time, whether vested or unvested, was assigned, transferred and surrendered by the holder thereof to the Issuer and thereafter cancelled in consideration for (A) a cash payment by or on behalf of the Issuer equal to the number of Shares into which such Option is then exercisable multiplied by the amount, if any, by which the Cash Consideration exceeds the exercise price per Share of such Option and (B) one CVR with respect to each Share into which such Option is then exercisable, in each case subject to applicable tax withholdings and other source deductions. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:54 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 8,804 | $0.00 Strike: $38.46 | $0.00 |
DisclosureSEC source: 0001415889-24-011681 · form4-04292024_090415.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 8,804 Underlying: Common Stock · 8,804 shares Expires 2034-04-25 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| April 25, 2024 Filed Apr 29, 2024 21:54 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 6,501 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-24-011681 · form4-04292024_090415.xml · nonDerivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,754 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) April 25, 2025 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| February 22, 2024 Filed Feb 26, 2024 22:54 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 30,000 | $0.00 Strike: $3.68 | $0.00 |
DisclosureSEC source: 0001209191-24-003958 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 30,000 Underlying: Common Stock · 30,000 shares Expires 2034-02-21 F1 · derivative.exercise_date: The option will vest in full on February 22, 2025, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 46,750 | $0.00 Strike: $4.12 | $0.00 |
DisclosureSEC source: 0000899243-23-016127 · doc4.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 46,750 Underlying: Common Stock · 46,750 shares Expires 2033-06-15 F3 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) substantially equal monthly installments following June 16, 2023, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 16, 2023 Filed Jun 21, 2023 20:05 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantRestricted Stock Units · Derivative | 33,150 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-016127 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 33,150 Underlying: Common Stock · 33,150 shares Expires not disclosed F1 · derivative.exercise_price: Each restricted stock unit ("RSU") represents a contingent right to receive one share of the Issuer's Common Stock. F2 · derivative.exercise_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. F2 · derivative.expiration_date: The RSUs vest in a single installment on the earlier of (i) the date of the next annual meeting of the Issuer's stockholders occurring after the date of grant or (ii) the first anniversary of the date of grant, in each case, subject to the Reporting Person's continued service through the applicable vesting date. Read SEC document |
| June 14, 2023 Filed Jun 14, 2023 17:06 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Opion (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $4.64 | $0.00 |
DisclosureSEC source: 0001209191-23-037091 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2033-06-13 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2024 or (ii) the 2024 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantOption to Purchase Common Stock · Derivative | 11,371 | $0.00 Strike: $31.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007690 · form4-05092023_100516.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 11,371 Underlying: Common Stock · 11,371 shares Expires 2033-05-05 F2 · derivative.exercise_date: Represents annual stock option grant under the Issuer's director compensation program. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. Read SEC document |
| May 05, 2023 Filed May 9, 2023 22:16 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 8,065 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-007690 · form4-05092023_100516.xml · nonDerivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 9,253 F1 · shares: Represents annual restricted stock unit ("RSU") grant under the Issuer's director compensation program. Each RSU represents the right to receive one share of common stock of the Issuer. This grant will vest in full on the earlier of (i) May 5, 2024 and (ii) the date of the Issuer's next annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 20,000 | Not disclosed Strike: $2.80 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 7 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 20,000 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,700 | Not disclosed Strike: $7.27 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 6 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,700 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,700 | Not disclosed Strike: $7.58 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 5 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,700 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 15,700 | Not disclosed Strike: $4.46 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 4 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,700 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 13,550 | Not disclosed Strike: $7.92 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 3 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 13,550 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 10,840 | Not disclosed Strike: $9.56 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 2 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 10,840 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| May 03, 2023 Filed May 4, 2023 07:43 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | Disposition to issuerStock Option (Right to Buy) · Derivative | 34,271 | Not disclosed Strike: $4.21 | Not disclosed |
DisclosureSEC source: 0001640455-23-000108 · wf-form4_168320060992986.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 34,271 shares Expires not disclosed F2 · price: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F1 · derivative.exercise_date: This Form 4 reports securities disposed of pursuant to the terms of the Merger Agreement entered into by and among the Issuer, Concentra Biosciences, LLC ("Parent") and Concentra Merger Sub, Inc., a direct and wholly-owned subsidiary of Parent ("Merger Sub"), dated as of March 26, 2023 (the "Merger Agreement"), pursuant to which Merger Sub completed a tender offer for the shares of common stock of the Issuer (each, a "Share") and thereafter merged with and into the Issuer (the "Merger") effective as of May 3, 2023 (the "Effective Time"). F2 · derivative.exercise_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. F2 · derivative.expiration_date: Pursuant to the terms of the Merger Agreement, at the Effective Time, each option to purchase Shares granted under an Issuer equity plan (each, a "Company Stock Option") that was outstanding and unvested immediately prior to the Effective Time vested in full. As of the Effective Time, each Company Stock Option that was outstanding immediately prior to the Effective Time was cancelled, and, in exchange therefor, the holder of such cancelled Company Stock Option was entitled to receive (without interest), in consideration of the cancellation of such Company Stock Option, (i) an amount in cash (less applicable tax withholdings) equal to the product of (x) the total number of Shares subject to such Company Stock Option immediately prior to the Effective Time multiplied by (y) the excess, if any, of $1.85 over the applicable exercise price per Share under such Company Stock Option and (ii) one contingent value right for each Share subject thereto. Read SEC document |
| February 23, 2023 Filed Feb 27, 2023 21:47 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.50 | $0.00 |
DisclosureSEC source: 0001209191-23-013207 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2033-02-22 F1 · derivative.exercise_date: The option will vest in full on February 23, 2024 subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 03, 2023 Filed Feb 7, 2023 21:06 UTC | HALOZYME THERAPEUTICS, INC. HALO · Entity 793 | GrantCommon Stock | 1,188 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-23-002070 · form4-02072023_090211.xml · nonDerivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,188 F1 · shares: Represents restricted stock units granted under the Issuer's director compensation program. Each stock unit represents the right to receive one share of common stock and is scheduled to vest on the earlier of (i) May 5, 2023 and (ii) the date of the Issuer's 2023 annual meeting of stockholders. These stock units are subject to a written deferral election under the Issuer's Directors Deferred Equity Compensation Plan pursuant to which shares of common stock are released to the reporting person upon completion of service as a director. Read SEC document |
| July 01, 2022 Filed Jul 1, 2022 21:01 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 500,000 | $0.00 Strike: $0.28 | $0.00 |
DisclosureSEC source: 0001104659-22-076895 · tm2220260-2_4seq1.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 500,000 Underlying: Ordinary Shares · 500,000 shares Expires 2032-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.23 based on an exchange rate of $U.S. 1.216007 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 24, 2022 Filed Jun 28, 2022 21:02 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 20,000 | $0.00 Strike: $2.80 | $0.00 |
DisclosureSEC source: 0001640455-22-000069 · wf-form4_165646451016548.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2032-06-24 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2023 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 17, 2022 Filed Jun 21, 2022 23:49 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 61,264 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0000899243-22-023505 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,264 Underlying: Common Stock · 61,264 shares Expires 2032-06-16 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 17, 2022, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 14, 2022 Filed Jun 22, 2022 19:07 UTC | Fusion Pharmaceuticals Inc. FUSN · Entity 11851 | GrantStock Opion (Right to Buy) · Derivative | 17,000 | $0.00 Strike: $3.60 | $0.00 |
DisclosureSEC source: 0001209191-22-038769 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,000 Underlying: Common Stock · 17,000 shares Expires 2032-06-13 F1 · derivative.exercise_date: This option fully vests on the earlier of (i) June 14, 2023 or (ii) the 2023 Annual Meeting of Shareholders of Fusion Pharmaceuticals Inc. Read SEC document |
| April 08, 2022 Filed Apr 12, 2022 20:55 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 21,347 | $0.00 Strike: $3.22 | $0.00 |
DisclosureSEC source: 0001209191-22-024163 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,347 Underlying: Common Stock · 21,347 shares Expires 2032-04-07 F1 · derivative.exercise_date: The option shall vest as follows: 25% of the shares subject to the option will vest and become exercisable October 8, 2022 and the remaining shares will vest in 18 equal monthly installments thereafter, subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| February 03, 2022 Filed Feb 5, 2022 01:48 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $2.72 | $0.00 |
DisclosureSEC source: 0001209191-22-007326 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2032-02-02 F1 · derivative.exercise_date: The option will vest in full on February 3, 2023 subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
| July 01, 2021 Filed Jul 2, 2021 21:00 UTC | Adaptimmune Therapeutics PLC ADAP · Entity 9824 | GrantOption to purchase Ordinary Shares · Derivative | 379,788 | $0.00 Strike: $0.71 | $0.00 |
DisclosureSEC source: 0001104659-21-088960 · tm2121284-1_4seq1.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 379,788 Underlying: Ordinary Shares · 379,788 shares Expires 2031-07-01 F1 · derivative.exercise_price: The exercise price was converted from GBP0.51 based on an exchange rate of $U.S. 1.3807 to GBP1.00. The actual exercise price will be the pounds sterling amount. Read SEC document |
| June 18, 2021 Filed Jun 21, 2021 21:35 UTC | Atea Pharmaceuticals, Inc. AVIR · Entity 5580 | GrantStock Option (Right to Buy) · Derivative | 34,025 | $0.00 Strike: $23.39 | $0.00 |
DisclosureSEC source: 0000899243-21-025045 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,025 Underlying: Common Stock · 34,025 shares Expires 2031-06-17 F1 · derivative.exercise_date: The option vests and becomes exercisable in twelve (12) equal monthly installments following June 18, 2021, such that the option shall be fully vested on the first anniversary of the date of grant, subject to the Reporting Person's continued service through each such vesting date. Read SEC document |
| June 18, 2021 Filed Jun 22, 2021 16:45 UTC | Jounce Therapeutics, Inc. JNCE · Entity 15754 | GrantStock Option (Right to Buy) · Derivative | 15,700 | $0.00 Strike: $7.27 | $0.00 |
DisclosureSEC source: 0001640455-21-000110 · wf-form4_162439469478970.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,700 Underlying: Common Stock · 15,700 shares Expires 2031-06-18 F1 · derivative.exercise_date: The option will vest in equal quarterly installments during the four quarters following the grant date, provided that if the Issuer's 2022 annual meeting of stockholders occurs before the one-year anniversary of the grant date, the unvested portion of the option will vest as of the date of such annual meeting, subject in each case to the Reporting Person's continued service on the Issuer's board of directors. Read SEC document |
| June 11, 2021 Filed Jun 12, 2021 00:31 UTC | Ovid Therapeutics Inc. OVID · Entity 5411 | GrantStock Option (Right to Buy) · Derivative | 15,000 | $0.00 Strike: $4.49 | $0.00 |
DisclosureSEC source: 0001209191-21-040081 · doc4.xml · derivative · entry 1 Duncan Barbara Gayle · CIK 0001353128 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 15,000 shares Expires 2031-06-10 F1 · derivative.exercise_date: The option will vest in full on June 11, 2022 subject to the Reporting Person's continuous service through such vesting date. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.